Flexion Therapeutics (NASDAQ:FLXN) posted its quarterly earnings data on Thursday. The specialty pharmaceutical company reported ($1.00) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.01) by $0.01, Fidelity Earnings reports. The firm had revenue of $21.79 million for the quarter, compared to analysts’ expectations of $18.85 million. Flexion Therapeutics had a negative net margin of 368.31% and a negative return on equity of 175.29%.
NASDAQ:FLXN traded down $0.69 during trading hours on Friday, reaching $16.43. The company’s stock had a trading volume of 1,132,400 shares, compared to its average volume of 622,178. Flexion Therapeutics has a 1 year low of $8.76 and a 1 year high of $17.82. The firm has a market capitalization of $655.05 million, a price-to-earnings ratio of -3.66 and a beta of 1.38. The firm has a 50-day simple moving average of $14.85 and a 200-day simple moving average of $12.36. The company has a debt-to-equity ratio of 3.95, a quick ratio of 7.33 and a current ratio of 7.80.
FLXN has been the topic of a number of analyst reports. Zacks Investment Research cut shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 8th. ValuEngine cut shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, October 25th. Northland Securities set a $20.00 target price on shares of Flexion Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, September 10th. Finally, BidaskClub upgraded shares of Flexion Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $23.57.
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.
Read More: What is channel trading?
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.